275 related articles for article (PubMed ID: 33113810)
1. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
[TBL] [Abstract][Full Text] [Related]
3. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Kawahata W; Asami T; Kiyoi T; Irie T; Taniguchi H; Asamitsu Y; Inoue T; Miyake T; Sawa M
J Med Chem; 2018 Oct; 61(19):8917-8933. PubMed ID: 30216722
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415
[TBL] [Abstract][Full Text] [Related]
7. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
[TBL] [Abstract][Full Text] [Related]
9. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
Yao X; Sun X; Jin S; Yang L; Xu H; Rao Y
J Med Chem; 2019 Jul; 62(14):6561-6574. PubMed ID: 31260299
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B
Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711
[TBL] [Abstract][Full Text] [Related]
12. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
13. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.
Pery N; Rizvi NB; Shafiq MI
J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204
[TBL] [Abstract][Full Text] [Related]
14. Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.
Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Babu Boga S; Alhassan AB; Yu W; Selyutin O; Yu Y; Anand R; Xu J; Kelly J; Duffy JL; Liu S; Yang C; Wu H; Cai J; Bennett C; Maloney KM; Tyagarajan S; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Zhang-Hoover J; Knemeyer I; Garlisi CG; Stivers P; Brandish PE; Hicks A; Kim R; Kozlowski JA
Bioorg Med Chem Lett; 2020 Sep; 30(17):127390. PubMed ID: 32738973
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
Dou D; Sha W; Diao Y; Su R; Qiao Y; Yu Z; Zhao Z; Li H; Chen Z; Xu Y
Bioorg Chem; 2022 Feb; 119():105541. PubMed ID: 34910982
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B
Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225
[TBL] [Abstract][Full Text] [Related]
17. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Liu J; Chen C; Wang D; Zhang J; Zhang T
Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
[TBL] [Abstract][Full Text] [Related]
18. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Angst D; Gessier F; Janser P; Vulpetti A; Wälchli R; Beerli C; Littlewood-Evans A; Dawson J; Nuesslein-Hildesheim B; Wieczorek G; Gutmann S; Scheufler C; Hinniger A; Zimmerlin A; Funhoff EG; Pulz R; Cenni B
J Med Chem; 2020 May; 63(10):5102-5118. PubMed ID: 32083858
[TBL] [Abstract][Full Text] [Related]
19. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series.
Liu Q; Batt DG; Chaudhry C; Lippy JS; Pattoli MA; Surti N; Xu S; Carter PH; Burke JR; Tino JA
Bioorg Med Chem Lett; 2018 Oct; 28(18):3080-3084. PubMed ID: 30097367
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]